Meganeuro ampoules 2 ml

It has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effects, and increases the body's resistance to stress. The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (neuroleptics).

1 ml of solution contains:

• Ethylmethylhydroxypyridine succinate - 50 mg;
• Excipients: water for injection 2 ml.

• acute cerebrovascular accidents;
• traumatic brain injury, consequences of traumatic brain injury;
• encephalopathy;
• autonomic dystonia syndrome;
• mild cognitive disorders of atherosclerotic origin;
• anxiety disorders in neurotic and neurosis-like conditions;
• acute myocardial infarction (from the first day) as part of complex therapy;
• primary open-angle glaucoma of various stages, as part of complex therapy;
• relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication with antipsychotic drugs;
• acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Method of administration and dose: IM or IV (stream or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Meganeuro is injected slowly over 5-7 minutes, and drip-wise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

For acute cerebrovascular accidents Meganeiro is used in the first 10-14 days - 200-500 mg intravenously 2-4 times a day, then 200-250 mg intramuscularly 2-3 times a day for 2 weeks.

For traumatic brain injury and consequences of traumatic brain injury Meganeuro is used for 10 - 15 days intravenously, 200 - 500 mg 2 - 4 times a day.

For discirculatory encephalopathy in the decompensation phase, Meganeuro should be prescribed intravenously or drip at a dose of 200 - 500 mg 1 - 2 times a day for 14 days. Then IM 100 - 250 mg / day over the next 2 weeks.

For course prophylaxis of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200 - 250 mg 2 times a day for 10 - 14 days.

For mild cognitive impairment in elderly patients and anxiety disorders, the drug is used intramuscularly in a daily dose of 100 - 300 mg/day for 14 - 30 days.

In case of acute myocardial infarction, as part of complex therapy, Meganeuro is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE).